Hormonal
Post-bariatric recurrent weight gain (RWG) can be effectively managed with FDA-approved anti-obesity medications (AOMs) such as GLP-1 receptor agonists (liraglutide, semaglutide), phentermine/topiramate, naltrexone/bupropion, and orlistat, which reduce weight regain or aid weight loss.
If you are gaining weight back after bariatric surgery, talk to your doctor about FDA-approved anti-obesity medications. Drugs like semaglutide (Ozempic/Wegovy) or liraglutide (Saxenda) are specifically approved and shown to help with weight loss and preventing regain. They work by affecting hormones that control hunger and stomach emptying. While they involve injections and can cause nausea, they are a potent tool to avoid more complex revisional surgeries.
Anti-obesity drugs can act as a potent supplementary treatment following BS, aiding in enhancing weight reduction after the procedure or averting the RWG (4, 5).
Source
Prognosticating post-bariatric surgery outcomes and management of postoperative recurrent weight gain and diabetes recurrence
Xiao He et al. · Frontiers in Nutrition · 2024
DOI 10.3389/fnut.2024.1510403
More from this paper
- Post-bariatric recurrent weight gain (RWG) can be managed with other FDA-approved anti-obesity medications including phentermine/topiramate, naltrexone/bupropion, and orlistat, which reduce weight regain or aid weight loss.Good
- Endoscopic interventions such as Endoscopic Sleeve Gastroplasty (ESG) and Transoral Outlet Reduction (TORe) are effective minimally invasive treatments for managing post-bariatric recurrent weight gain (RWG).Good
- Conversional surgeries (e.g., RYGB, SADI-S, DS) are effective for managing post-bariatric recurrent weight gain (RWG) and diabetes recurrence, but carry higher risks of complications compared to primary surgery.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →